低钙血症 中国就医指南

Hypocalcemia is a common endocrine disorder characterized by abnormally low serum calcium concentration—typically defined as total serum calcium <8.5 mg/dL (2.12 mmol/L) or ionized calcium <1.1 mmol/L. Calcium is essential for neuromuscular excitability, cardiac contractility, coagulation, and bone mineralization; thus, its deficiency triggers multisystem dysfunction. Pathogenesis involves disruptions in the tightly regulated calcium homeostasis governed by parathyroid hormone (PTH), vitamin D metabolism, and renal handling. Primary causes include hypoparathyroidism (post-surgical, autoimmune, or genetic), vitamin D deficiency or resistance, chronic kidney disease (impaired calcitriol synthesis and phosphate retention), acute pancreatitis (calcium sequestration), and severe magnesium deficiency (which impairs PTH secretion and action). Medications such as bisphosphonates, denosumab, calcimimetics, and certain antibiotics (e.g., foscarnet) also contribute. Epidemiologically, hypocalcemia affects approximately 1–2% of hospitalized patients, with higher prevalence among post-thyroidectomy or post-parathyroidectomy patients (up to 20–30% transiently, 1–5% chronically). In community settings, prevalence is lower but rises significantly in elderly populations, chronic dialysis patients (30–50%), and those with malabsorptive disorders. Key risk factors include recent neck surgery, autoimmune polyglandular syndrome, celiac disease, Crohn’s disease, chronic alcohol use, renal insufficiency, and prolonged proton pump inhibitor use. Symptoms range from mild (paresthesias, muscle cramps, fatigue) to life-threatening (laryngospasm, bronchospasm, seizures, QT prolongation, ventricular arrhythmias). Chronic hypocalcemia may lead to basal ganglia calcification, cataracts, dental enamel hypoplasia, and cognitive impairment. Quality of life is substantially impacted: patients report persistent anxiety, sleep disturbances, reduced work productivity, social withdrawal due to symptom unpredictability, and treatment burden—including frequent monitoring, dietary restrictions, and lifelong supplementation. Untreated or poorly managed cases increase hospitalization risk and long-term morbidity. Early diagnosis via serum calcium, albumin-adjusted calcium, ionized calcium, PTH, 25(OH)D, magnesium, and renal function tests is critical. Differential diagnosis must exclude pseudohypocalcemia (hypoalbuminemia) and assay interference. Management requires identifying and addressing the underlying etiology—not merely correcting calcium levels—while avoiding rebound hypercalcemia or ectopic calcification. Patient education on symptom recognition, emergency response (e.g., oral calcium gel for acute tetany), and adherence to vitamin D analogs (e.g., calcitriol) is integral to sustainable outcomes.

# 低钙血症治疗方案与费用明细（内分泌科）

一、非手术/保守治疗方案

适用人群：轻中度症状、维生素D缺乏、慢性肾病早期、术后暂时性低钙者。

• •口服补钙+活性维生素D（如碳酸钙600mg bid + 骨化三醇0.25–0.5μg/d）：药费 ¥30–¥120/月
• •静脉补钙（10%葡萄糖酸钙10mL iv慢推，需心电监护）：单次治疗费 ¥80–¥200（含监护）
• •必要检查：血钙、磷、PTH、25(OH)D、肾功能、心电图：¥320–¥580/套

二、病因导向介入治疗

适用人群：明确继发于甲状旁腺功能减退、肿瘤相关性或吸收障碍者。

• •甲状旁腺移植（实验性，限临床研究单位）：术前评估（颈部超声+99mTc-MIBI显像+PTH动态监测）¥2,800–¥4,500；手术及住院（7–10天）¥80,000–¥120,000（含免疫抑制剂）
• •恶性肿瘤相关低钙（如骨转移）：双膦酸盐/地诺单抗调整：药费 ¥2,000–¥6,500/月

三、复杂/耐药/并发症方案

适用人群：顽固性低钙伴癫痫发作、喉痉挛、心律失常或长期依赖静脉钙者。

• •多学科联合管理（内分泌+肾内科+营养科）：年度随访套餐（含基因检测*CASR/PTH基因*、骨密度、尿钙排泄率）¥4,200–¥7,600
• •长期皮下注射PTH（特立帕肽）：¥15,000–¥22,000/月（医保限符合适应证者）

方案快速选择指南

• •预算有限/初诊轻症：首选口服补钙+维生素D+基础检查（总约¥600内）
• •反复发作/病因未明：加做PTH+25(OH)D+颈部超声（总¥1,200–¥2,000），启动病因筛查
• •危及生命/急性喉痉挛：立即静脉补钙+ICU监护（单次¥1,500起）
• •难治性甲旁减：转诊至国家级内分泌代谢专科中心评估PTH替代或移植可行性